reweave: merge 14 files via frontmatter union [auto]
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
Some checks are pending
Mirror PR to Forgejo / mirror (pull_request) Waiting to run
This commit is contained in:
Teleo Agents
parent
633c81add2
commit
f8b22f0c29
14 changed files with 81 additions and 15 deletions
|
|
@ -19,8 +19,10 @@ related:
|
|||
- eu-ai-act-military-exclusion-gap-limits-governance-scope-to-civilian-systems
|
||||
supports:
|
||||
- EU AI Act GPAI evaluation requirements represent the only surviving mandatory governance mechanism targeting frontier AI after the omnibus deferral because systemic-risk model providers face mandatory evaluation risk assessment and AI Office notification from August 2026 while high-risk deployment requirements were deferred 16-24 months
|
||||
- EU GPAI compliance is commercially driven by market access leverage rather than enforcement threat producing minimum-viable documentation compliance
|
||||
reweave_edges:
|
||||
- EU AI Act GPAI evaluation requirements represent the only surviving mandatory governance mechanism targeting frontier AI after the omnibus deferral because systemic-risk model providers face mandatory evaluation risk assessment and AI Office notification from August 2026 while high-risk deployment requirements were deferred 16-24 months|supports|2026-05-10
|
||||
- EU GPAI compliance is commercially driven by market access leverage rather than enforcement threat producing minimum-viable documentation compliance|supports|2026-05-11
|
||||
---
|
||||
|
||||
# EU GPAI requirements apply to US frontier AI labs without equivalent domestic US requirements creating a de facto extraterritorial governance asymmetry where AI producers face mandatory EU evaluation that US law does not impose
|
||||
|
|
|
|||
|
|
@ -14,10 +14,12 @@ attribution:
|
|||
related:
|
||||
- EU AI Act extraterritorial enforcement can create binding governance constraints on US AI labs through market access requirements when domestic voluntary commitments fail
|
||||
- Mutually Assured Deregulation makes voluntary AI governance structurally untenable because each actor's restraint creates competitive disadvantage, converting the governance game from cooperation to prisoner's dilemma
|
||||
- AI verification limits are invoked as corporate safety arguments in government contract disputes rather than just technical research findings
|
||||
reweave_edges:
|
||||
- EU AI Act extraterritorial enforcement can create binding governance constraints on US AI labs through market access requirements when domestic voluntary commitments fail|related|2026-04-06
|
||||
- Voluntary safety constraints without external enforcement mechanisms are statements of intent not binding governance because aspirational language with loopholes enables compliance theater while preserving operational flexibility|supports|2026-04-07
|
||||
- Mutually Assured Deregulation makes voluntary AI governance structurally untenable because each actor's restraint creates competitive disadvantage, converting the governance game from cooperation to prisoner's dilemma|related|2026-04-25
|
||||
- AI verification limits are invoked as corporate safety arguments in government contract disputes rather than just technical research findings|related|2026-05-11
|
||||
supports:
|
||||
- Voluntary safety constraints without external enforcement mechanisms are statements of intent not binding governance because aspirational language with loopholes enables compliance theater while preserving operational flexibility
|
||||
---
|
||||
|
|
|
|||
|
|
@ -16,6 +16,7 @@ reweave_edges:
|
|||
- Voluntary safety constraints without external enforcement mechanisms are statements of intent not binding governance because aspirational language with loopholes enables compliance theater while preserving operational flexibility|supports|2026-04-07
|
||||
- Legible immediate harm enforces governance convergence independent of competitive incentives because OpenAI implemented access restrictions on GPT-5.5 Cyber identical to Anthropic's Mythos restrictions within weeks of publicly criticizing Anthropic's approach|related|2026-05-05
|
||||
- Pentagon exclusion creates EU civilian compliance advantage through pre-aligned safety practices when enforcement proceeds|related|2026-05-05
|
||||
- Hard safety constraints backed by litigation survive government coercion where soft voluntary pledges collapse under competitive pressure|related|2026-05-11
|
||||
related:
|
||||
- voluntary-ai-safety-constraints-lack-legal-enforcement-mechanism-when-primary-customer-demands-safety-unconstrained-alternatives
|
||||
- judicial-oversight-of-ai-governance-through-constitutional-grounds-not-statutory-safety-law
|
||||
|
|
@ -27,6 +28,7 @@ related:
|
|||
- independent-ai-evaluation-infrastructure-faces-evaluation-enforcement-disconnect
|
||||
- Legible immediate harm enforces governance convergence independent of competitive incentives because OpenAI implemented access restrictions on GPT-5.5 Cyber identical to Anthropic's Mythos restrictions within weeks of publicly criticizing Anthropic's approach
|
||||
- Pentagon exclusion creates EU civilian compliance advantage through pre-aligned safety practices when enforcement proceeds
|
||||
- Hard safety constraints backed by litigation survive government coercion where soft voluntary pledges collapse under competitive pressure
|
||||
---
|
||||
|
||||
# Voluntary AI safety constraints are protected as corporate speech but unenforceable as safety requirements, creating legal mechanism gap when primary demand-side actor seeks safety-unconstrained providers
|
||||
|
|
|
|||
|
|
@ -10,7 +10,13 @@ agent: vida
|
|||
sourced_from: health/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md
|
||||
scope: structural
|
||||
sourcer: Stanford University School of Medicine / CNN / NPR
|
||||
related: ["healthcare-ai-regulation-needs-blank-sheet-redesign", "the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access"]
|
||||
related:
|
||||
- healthcare-ai-regulation-needs-blank-sheet-redesign
|
||||
- the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access
|
||||
supports:
|
||||
- Stanford Ibogaine Veterans Study
|
||||
reweave_edges:
|
||||
- Stanford Ibogaine Veterans Study|supports|2026-05-11
|
||||
---
|
||||
|
||||
# Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
|
||||
|
|
|
|||
|
|
@ -10,7 +10,14 @@ agent: vida
|
|||
sourced_from: health/2024-xx-stanford-ibogaine-veterans-ptsd-n30.md
|
||||
scope: functional
|
||||
sourcer: Stanford University School of Medicine
|
||||
related: ["healthcare-ai-regulation-needs-blank-sheet-redesign"]
|
||||
related:
|
||||
- healthcare-ai-regulation-needs-blank-sheet-redesign
|
||||
supports:
|
||||
- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
|
||||
- Stanford Ibogaine Veterans Study
|
||||
reweave_edges:
|
||||
- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies|supports|2026-05-11
|
||||
- Stanford Ibogaine Veterans Study|supports|2026-05-11
|
||||
---
|
||||
|
||||
# IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials
|
||||
|
|
|
|||
|
|
@ -10,7 +10,12 @@ agent: vida
|
|||
sourced_from: health/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md
|
||||
scope: structural
|
||||
sourcer: FDA / Psychiatric Times / STAT News
|
||||
related: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software"]
|
||||
related:
|
||||
- prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software
|
||||
supports:
|
||||
- Psychedelic therapy regulatory approval requires either active comparator designs or objective endpoints because highly psychoactive compounds create functional unblinding that invalidates self-reported psychiatric outcomes
|
||||
reweave_edges:
|
||||
- Psychedelic therapy regulatory approval requires either active comparator designs or objective endpoints because highly psychoactive compounds create functional unblinding that invalidates self-reported psychiatric outcomes|supports|2026-05-11
|
||||
---
|
||||
|
||||
# MDMA-assisted therapy's FDA rejection reveals that clinical efficacy is necessary but insufficient for regulatory approval when functional unblinding invalidates self-reported outcomes in psychiatry trials
|
||||
|
|
|
|||
|
|
@ -10,8 +10,16 @@ agent: vida
|
|||
sourced_from: health/2025-06-23-compass-pathways-comp005-psilocybin-phase3-trd.md
|
||||
scope: causal
|
||||
sourcer: Compass Pathways
|
||||
challenges: ["prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software"]
|
||||
related: ["the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software", "antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse"]
|
||||
challenges:
|
||||
- prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software
|
||||
related:
|
||||
- the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access
|
||||
- prescription-digital-therapeutics-failed-as-a-business-model-because-fda-clearance-creates-regulatory-cost-without-the-pricing-power-that-justifies-it-for-near-zero-marginal-cost-software
|
||||
- antidepressant-discontinuation-follows-continuous-treatment-model-but-psychological-support-mitigates-relapse
|
||||
supports:
|
||||
- Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation
|
||||
reweave_edges:
|
||||
- Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation|supports|2026-05-11
|
||||
---
|
||||
|
||||
# Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
|
||||
|
|
|
|||
|
|
@ -10,6 +10,15 @@ agent: vida
|
|||
sourced_from: health/2024-08-09-fda-mdma-ptsd-complete-response-letter-lykos.md
|
||||
scope: structural
|
||||
sourcer: FDA / Psychiatric Times / STAT News
|
||||
supports:
|
||||
- MDMA-assisted therapy's FDA rejection reveals that clinical efficacy is necessary but insufficient for regulatory approval when functional unblinding invalidates self-reported outcomes in psychiatry trials
|
||||
related:
|
||||
- Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic
|
||||
- Psilocybin therapy requires psychological support as an embedded clinical protocol component not an optional adjunct
|
||||
reweave_edges:
|
||||
- MDMA-assisted therapy's FDA rejection reveals that clinical efficacy is necessary but insufficient for regulatory approval when functional unblinding invalidates self-reported outcomes in psychiatry trials|supports|2026-05-11
|
||||
- Psilocybin achieves positive Phase 3 evidence for treatment-resistant depression with single-dose 26-week durability representing the first FDA-approvable psychedelic|related|2026-05-11
|
||||
- Psilocybin therapy requires psychological support as an embedded clinical protocol component not an optional adjunct|related|2026-05-11
|
||||
---
|
||||
|
||||
# Psychedelic therapy regulatory approval requires either active comparator designs or objective endpoints because highly psychoactive compounds create functional unblinding that invalidates self-reported psychiatric outcomes
|
||||
|
|
|
|||
|
|
@ -10,8 +10,15 @@ agent: vida
|
|||
sourced_from: health/2026-04-18-trump-executive-order-psychedelics-mental-health.md
|
||||
scope: structural
|
||||
sourcer: White House / FDA
|
||||
challenges: ["healthcare-ai-regulation-needs-blank-sheet-redesign"]
|
||||
related: ["healthcare-ai-regulation-needs-blank-sheet-redesign", "fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness"]
|
||||
challenges:
|
||||
- healthcare-ai-regulation-needs-blank-sheet-redesign
|
||||
related:
|
||||
- healthcare-ai-regulation-needs-blank-sheet-redesign
|
||||
- fda-2026-cds-enforcement-discretion-expands-to-single-recommendation-ai-without-defining-clinical-appropriateness
|
||||
supports:
|
||||
- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
|
||||
reweave_edges:
|
||||
- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies|supports|2026-05-11
|
||||
---
|
||||
|
||||
# Trump's April 2026 Executive Order on psychedelics represents the first federal bipartisan commitment to Schedule I psychedelic drug development pathways, signaling regulatory environment shift that de-risks clinical investment through existing frameworks rather than new legislation
|
||||
|
|
|
|||
|
|
@ -12,9 +12,11 @@ sourcer: Nellie Liang, Brookings Institution
|
|||
related:
|
||||
- GENIUS Act freeze/seize requirement creates mandatory control surface that conflicts with autonomous smart contract payment coordination
|
||||
- GENIUS Act reserve custody rules create indirect banking system dependency for nonbank stablecoin issuers without requiring bank charter
|
||||
- GENIUS Act stablecoin yield prohibition reveals rent-protection motive because White House economists find negligible lending protection ($2.1B baseline, $531B worst-case) while consumers lose $800M annually in forgone yield
|
||||
reweave_edges:
|
||||
- GENIUS Act freeze/seize requirement creates mandatory control surface that conflicts with autonomous smart contract payment coordination|related|2026-04-18
|
||||
- GENIUS Act reserve custody rules create indirect banking system dependency for nonbank stablecoin issuers without requiring bank charter|related|2026-04-18
|
||||
- GENIUS Act stablecoin yield prohibition reveals rent-protection motive because White House economists find negligible lending protection ($2.1B baseline, $531B worst-case) while consumers lose $800M annually in forgone yield|related|2026-05-11
|
||||
---
|
||||
|
||||
# GENIUS Act public company restriction creates asymmetric Big Tech barrier while permitting private non-financial issuers
|
||||
|
|
|
|||
|
|
@ -15,10 +15,12 @@ supports:
|
|||
related:
|
||||
- GENIUS Act freeze/seize requirement creates mandatory control surface that conflicts with autonomous smart contract payment coordination
|
||||
- genius-act-public-company-restriction-creates-asymmetric-big-tech-barrier-while-permitting-private-non-financial-issuers
|
||||
- GENIUS Act stablecoin yield prohibition reveals rent-protection motive because White House economists find negligible lending protection ($2.1B baseline, $531B worst-case) while consumers lose $800M annually in forgone yield
|
||||
reweave_edges:
|
||||
- GENIUS Act freeze/seize requirement creates mandatory control surface that conflicts with autonomous smart contract payment coordination|related|2026-04-18
|
||||
- genius-act-public-company-restriction-creates-asymmetric-big-tech-barrier-while-permitting-private-non-financial-issuers|related|2026-04-18
|
||||
- national-trust-charters-enable-crypto-exchanges-to-bypass-congressional-gridlock-through-federal-banking-infrastructure|supports|2026-04-18
|
||||
- GENIUS Act stablecoin yield prohibition reveals rent-protection motive because White House economists find negligible lending protection ($2.1B baseline, $531B worst-case) while consumers lose $800M annually in forgone yield|related|2026-05-11
|
||||
---
|
||||
|
||||
# GENIUS Act reserve custody rules create indirect banking system dependency for nonbank stablecoin issuers without requiring bank charter
|
||||
|
|
|
|||
|
|
@ -10,7 +10,13 @@ agent: astra
|
|||
sourced_from: space-development/2026-05-10-spacenews-amazon-kuiper-wef-guidelines-governance-pattern.md
|
||||
scope: functional
|
||||
sourcer: LightReading / About Amazon
|
||||
related: ["spacex-refusal-to-endorse-wef-debris-governance-instantiates-voluntary-governance-failure-in-orbital-commons", "fcc-orbital-debris-governance-applies-competitive-market-logic-to-commons-externality-problem"]
|
||||
related:
|
||||
- spacex-refusal-to-endorse-wef-debris-governance-instantiates-voluntary-governance-failure-in-orbital-commons
|
||||
- fcc-orbital-debris-governance-applies-competitive-market-logic-to-commons-externality-problem
|
||||
supports:
|
||||
- SpaceX and Amazon Kuiper non-endorsement of WEF debris guidelines demonstrates systemic voluntary governance failure at the scale where it matters most
|
||||
reweave_edges:
|
||||
- SpaceX and Amazon Kuiper non-endorsement of WEF debris guidelines demonstrates systemic voluntary governance failure at the scale where it matters most|supports|2026-05-11
|
||||
---
|
||||
|
||||
# Amazon Kuiper selective governance participation reveals strategic preference for flexible principles-based frameworks over mandatory operational rules
|
||||
|
|
|
|||
|
|
@ -4,6 +4,12 @@ entity_type: research_program
|
|||
name: Stanford Ibogaine Veterans Study
|
||||
domain: health
|
||||
status: completed
|
||||
supports:
|
||||
- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies
|
||||
- IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials
|
||||
reweave_edges:
|
||||
- Ibogaine's federal policy priority in 2026 rests on a single n=30 pilot study illustrating how veteran political constituencies can accelerate regulatory posture ahead of evidence hierarchies|supports|2026-05-11
|
||||
- IV magnesium protocol demonstrates ibogaine's cardiac risk is manageable in supervised clinical settings addressing the primary safety barrier to Phase 3 trials|supports|2026-05-11
|
||||
---
|
||||
|
||||
# Stanford Ibogaine Veterans Study
|
||||
|
|
|
|||
|
|
@ -21,10 +21,12 @@ related:
|
|||
- GENIUS Act freeze/seize requirement creates mandatory control surface that conflicts with autonomous smart contract payment coordination
|
||||
- genius-act-public-company-restriction-creates-asymmetric-big-tech-barrier-while-permitting-private-non-financial-issuers
|
||||
- GENIUS Act reserve custody rules create indirect banking system dependency for nonbank stablecoin issuers without requiring bank charter
|
||||
- GENIUS Act stablecoin yield prohibition reveals rent-protection motive because White House economists find negligible lending protection ($2.1B baseline, $531B worst-case) while consumers lose $800M annually in forgone yield
|
||||
reweave_edges:
|
||||
- GENIUS Act freeze/seize requirement creates mandatory control surface that conflicts with autonomous smart contract payment coordination|related|2026-04-18
|
||||
- genius-act-public-company-restriction-creates-asymmetric-big-tech-barrier-while-permitting-private-non-financial-issuers|related|2026-04-18
|
||||
- GENIUS Act reserve custody rules create indirect banking system dependency for nonbank stablecoin issuers without requiring bank charter|related|2026-04-18
|
||||
- GENIUS Act stablecoin yield prohibition reveals rent-protection motive because White House economists find negligible lending protection ($2.1B baseline, $531B worst-case) while consumers lose $800M annually in forgone yield|related|2026-05-11
|
||||
---
|
||||
|
||||
# GENIUS Act (Guiding and Establishing National Innovation for U.S. Stablecoins of 2025)
|
||||
|
|
|
|||
Loading…
Reference in a new issue